Penumbra, Inc. (FRA:0P8)

Market Cap	10.95B +24.4%
Revenue (ttm)	1.32B +17.6%
Net Income	140.56M +8.7%
EPS	3.56 +8.8%
Shares Out	n/a
PE Ratio	77.89
Forward PE	58.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	276.60
Previous Close	277.60
Day's Range	276.20 - 276.60
52-Week Range	193.10 - 306.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2004
• Employees: 4,700
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0P8

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error